Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Part D Formulary Edits: CMS Focus On Covering All Labeled Uses Unwarranted, PCMA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Pharmacy benefit managers express alarm that CMS is shifting on its definition of a medically-accepted indication for Medicare drug coverage.

You may also be interested in...



Medicare Plans’ Preferential Coverage For Off-Label Drugs Debated

A debate is brewing over how Medicare should handle plans' step-therapy practices that encourage beneficiaries to try an off-label treatment before coverage is granted for a drug with an FDA-approved indication

Medicare Plans’ Preferential Coverage For Off-Label Drugs Debated

A debate is brewing over how Medicare should handle plans' step-therapy practices that encourage beneficiaries to try an off-label treatment before coverage is granted for a drug with an FDA-approved indication

Part D In 2010: No Reference Pricing, More CMS Scrutiny Of Formulary Edits

The last CMS 1draft "call letter" to Medicare Part D contractors to be issued under the current administration emphasizes familiar themes - concern with information transparency and ensuring appropriate access to drugs - and includes little in the way of drug coverage policy changes

Related Content

Topics

UsernamePublicRestriction

Register

PS069097

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel